country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-B1075A

Copy Link Print Information

Fosfomycin

(Synonyms: MK-0955)

15 Cited Publications

Customer Review

Based on 15 publication(s) in Google Scholar

Fosfomycin (MK-0955) is a broad-spectrum antibiotic. Fosfomycin can cross blood-brain barrier penetrating, and irreversibly inhibits an early stage in cell wall synthesis. Fosfomycin shows anti-bacteria activity for a range of bacteria, including multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) bacteria.

For research use only. We do not sell to patients.

CAS No.: 23155-02-4
Formula: C₃H₇O₄P
Molecular Weight:138.06

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (274 KB)

Fosfomycin Chemical Structure

CAS No.: 23155-02-4

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vivo
Chemical Information
Publications (15)
Purity & Documentation
References
Calculators
Help & FAQs
Bioz

Biological Activity

Description

All Antibiotic Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A-431	IC₅₀	≥100 μM Compound: Fosfomycin	Cytotoxicity against human A431 cells after 72 hrs by crystal violet staining method Cytotoxicity against human A431 cells after 72 hrs by crystal violet staining method	[PMID: 23266177]
Calu-6	IC₅₀	≥100 μM Compound: Fosfomycin	Cytotoxicity against human Calu6 cells after 72 hrs by crystal violet staining method Cytotoxicity against human Calu6 cells after 72 hrs by crystal violet staining method	[PMID: 23266177]
CAPAN-1	IC₅₀	≥100 μM Compound: Fosfomycin	Cytotoxicity against human Capan1 cells after 72 hrs by crystal violet staining method Cytotoxicity against human Capan1 cells after 72 hrs by crystal violet staining method	[PMID: 23266177]
Ca-Ski	IC₅₀	≥100 μM Compound: Fosfomycin	Cytotoxicity against human CaSki cells after 72 hrs by crystal violet staining method Cytotoxicity against human CaSki cells after 72 hrs by crystal violet staining method	[PMID: 23266177]
HaCaT	IC₅₀	≥100 μM Compound: Fosfomycin	Cytotoxicity against human HaCaT cells after 72 hrs by crystal violet staining method Cytotoxicity against human HaCaT cells after 72 hrs by crystal violet staining method	[PMID: 23266177]
MeWo	IC₅₀	≥100 μM Compound: Fosfomycin	Cytotoxicity against human MeWo cells after 72 hrs by crystal violet staining method Cytotoxicity against human MeWo cells after 72 hrs by crystal violet staining method	[PMID: 23266177]

In Vivo

Fosfomycin (80 mg/kg; i.v. or p.o.) displays the protective effect on the nephrotoxicity of double beckacin, and is not affected by different administration routes in rats^[3].
Pharmacokinetic of Fosfomycin in Rats^[4]

Dibekacin Dose (mg)	V_dss (l/kg)	β (min^-1⁾	T_1/2 (min)	Urinary recovery (%)
30	0.261	0.0244	28.4	85

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Fischer 344 rats^[3]
Dosage:

320 mg/kg
Administration:

Intramuscular injection, 5 schedules: 1 h, 0.5 h earlier than dibekacin, concomitantly, 0.5 h later and 1 h later; 11 days
Result:

Reduced polyuria, proteinuria, enzymes and cytosine caused by dibecacin (40 mg/kg), followed by the previous treatment.

Animal Model:

Dehydrated Wistar rat with acute renal failure (8-week-old)^[4]
Dosage:

120 mg/kg
Administration:

Intravenous injection; once
Result:

Recovered the exclusion rate of rats basically to normal, and improved the nephrotoxicity parameters.
Protects proximal tubular lysosomes from aminoglycosides by inhibiting myeloid formation and protecting the integrity of lysosomal membrane of rats treated with double bekacin.

Chemical Information

CAS No. 23155-02-4
Molecular Weight 138.06
Formula C₃H₇O₄P
SMILES

C[C@@H]1O[C@@H]1P(O)(O)=O
Synonyms

MK-0955
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Publications (15)

All

Sort by:

Journal Impact Factor

Nat Commun

Antimicrobial resistance and population genomics of multidrug-resistant Escherichia coli in pig farms in mainland China. [Abstract]

2022 Mar 2;13(1):1116. PMID: 35236849
MedComm (2020)

Novel antibiotics against Staphylococcus aureus without detectable resistance by targeting proton motive force and FtsH. [Abstract]

2025 Jan 8;6(1):e70046. PMID: 39781293
J Exp Med

Antibiotic use in early life impairs MAIT cell-mediated immunity in adulthood. [Abstract]

2026 Mar 2;223(3):e20241287. PMID: 41400657
Front Cell Infect Microbiol

Fosfomycin Protects Mice From Staphylococcus aureus Pneumonia Caused by α-Hemolysin in Extracellular Vesicles by Inhibiting MAPK-Regulated NLRP3 Inflammasomes. [Abstract]

2019 Jul 15:9:253. PMID: 31380296
Molecules

Seeking Correlation Among Porin Permeabilities and Minimum Inhibitory Concentrations Through Machine Learning: A Promising Route to the Essential Molecular Descriptors. [Abstract]

2025 Mar 9;30(6):1224. PMID: 40142001
Antibiotics (Basel)

Rapid Detection of Multiple Classes of β-Lactam Antibiotics in Blood Using an NDM-1 Biosensing Assay. [Abstract]

2021 Sep 14;10(9):1110. PMID: 34572692
Microbiol Spectr

Sub-inhibitory concentrations of fosfomycin enhance Staphylococcus aureus biofilm formation by a sarA-dependent mechanism. [Abstract]

2025 Sep 2;13(9):e0152125. PMID: 40689791
ACS Infect Dis

Loratadine Derivative Lo-7: A Weapon against Drug-Resistant Enterococcus and Streptococcal Infections. [Abstract]

2024 Aug 9;10(8):2961-2977. PMID: 39066703
Microb Pathog

Sub-minimum inhibitory concentrations of fosfomycin enhance Staphylococcus aureus virulence through the agr-PSM pathway. [Abstract]

2026 Jan:210:108138. PMID: 41429753
J Antibiot (Tokyo)

In vitro assessment of the synergistic effects of cefotaxime, colistin, and fosfomycin combinations against foodborne resistant Escherichia coli and Salmonella isolates. [Abstract]

2025 Mar;78(4):265-273. PMID: 39910346
Infect Genet Evol

Polymyxin B combined with amikacin delays the resistance of Klebsiella pneumoniae to polymyxin B by modulating the expression of NlpE. [Abstract]

2025 Sep:133:105780. PMID: 40480594
J Med Microbiol

In vitro activities of daptomycin combined with fosfomycin or rifampin on planktonic and adherent linezolid-resistant isolates of Enterococcus faecalis. [Abstract]

2019 Mar;68(3):493-502. PMID: 30882300
Indian J Med Microbiol

Can aztreonam/avibactam combined with fosfomycin be a treatment option for infections caused by NDM-producing Pseudomonas aeruginosa?. [Abstract]

2026 May 14:62:101146. PMID: 42140317
bioRxiv

2025 January 19.
bioRxiv

2024 May 10.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (274 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Falagas ME, et al. Fosfomycin. Clin Microbiol Rev. 2016 Apr. 29(2):321-47. [Content Brief]

[2]. Dijkmans AC, et al. Fosfomycin: Pharmacological, Clinical and Future Perspectives. Antibiotics (Basel). 2017 Oct 31. 6(4):24. [Content Brief]

[3]. Inouye S, et al. Mode of protective action of fosfomycin against dibekacin-induced nephrotoxicity in the dehydrated rats. J Pharmacobiodyn. 1982 Dec. 5(12):941-50. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

100 mg

Get Quote In-stock